Grass pollen immunotherapy: where are we now.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Immunotherapy

• Publication date

  2016-03-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/imt.16.1PMID 26973122
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Distinct modulation of allergic T cell responses by subcutaneous vs. sublingual allergen‐specific immunotherapy

  2016cited by this paper
• Pretreatment IgE sensitization patterns determine the molecular profile of the IgG4 response during updosing of subcutaneous immunotherapy with timothy grass pollen extract.

  2016cited by this paper
• Effector cell signature in peripheral blood following nasal allergen challenge in grass pollen allergic individuals

  2015cited by this paper
• Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen‐specific basophil response; a real‐life, nonrandomized controlled study

  2015cited by this paper
• Specific IgE recognition of pollen allergens from subtropic grasses in patients from the subtropics.

  2015cited by this paper
• Total transcriptome, proteome, and allergome of Johnson grass pollen, which is important for allergic rhinitis in subtropical regions.

  2015cited by this paper
• Effect of grass pollen immunotherapy on clinical and local immune response to nasal allergen challenge

  2015cited by this paper
• Fel d 1‐derived synthetic peptide immuno‐regulatory epitopes show a long‐term treatment effect in cat allergic subjects

  2015cited by this paper
• Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens

  2015cited by this paper
• Inhibition of allergen‐dependent IgE activity by antibodies of the same specificity but different class

  2015cited by this paper
• Prolonged efficacy of the 300IR 5-grass pollen tablet up to 2 years after treatment cessation, as measured by a recommended daily combined score

  2015cited by this paper
• SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.

  2015cited by this paper
• Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients.

  2015cited by this paper
• Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy

  2015cited by this paper
• Grass pollen allergens globally: the contribution of subtropical grasses to burden of allergic respiratory diseases

  2014cited by this paper
• Group 2 Innate Lymphoid Cells Are Critical for the Initiation of Adaptive T Helper 2 Cell-Mediated Allergic Lung Inflammation

  2014cited by this paper
• Grass tablet sublingual immunotherapy downregulates the TH2 cytokine response followed by regulatory T-cell generation.

  2014cited by this paper
• Allergen challenge in allergic rhinitis rapidly induces increased peripheral blood type 2 innate lymphoid cells that express CD84.

  2014cited by this paper
• Early improvement in basophil sensitivity predicts symptom relief with grass pollen immunotherapy.

  2014cited by this paper
• Immunological comparison of allergen immunotherapy tablet treatment and subcutaneous immunotherapy against grass allergy

  2014cited by this paper
• Association between specific timothy grass antigens and changes in TH1- and TH2-cell responses following specific immunotherapy.

  2014cited by this paper
• Immunological mechanisms of sublingual immunotherapy

  2014cited by this paper
• Grass‐specific CD4+ T‐cells exhibit varying degrees of cross‐reactivity, implications for allergen‐specific immunotherapy

  2014cited by this paper
• Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy

  2014cited by this paper
• Dissection of the IgE and T-cell recognition of the major group 5 grass pollen allergen Phl p 5.

  2014cited by this paper
• Novel immunotherapy vaccine development

  2014cited by this paper
• SQ HDM SLIT-tablet (ALK) in treatment of asthma--post hoc results from a randomised trial.

  2014cited by this paper
• Seasonal increases in peripheral innate lymphoid type 2 cells are inhibited by subcutaneous grass pollen immunotherapy.

  2014cited by this paper
• Specific immunotherapy modifies allergen-specific CD4(+) T-cell responses in an epitope-dependent manner.

  2014cited by this paper
• Lipoxin A4 Regulates Natural Killer Cell and Type 2 Innate Lymphoid Cell Activation in Asthma

  2013cited by this paper
• Innate lymphoid cells — a proposal for uniform nomenclature

  2013cited by this paper
• Dendritic cells of the oral mucosa

  2013cited by this paper
• The identification of potentially pathogenic and therapeutic epitopes from common human allergens.

  2013cited by this paper
• Protocol for a double-blind randomised controlled trial of low dose intradermal grass pollen immunotherapy versus a histamine control on symptoms and medication use in adults with seasonal allergic rhinitis (PollenLITE)

  2013cited by this paper
• IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses.

  2013cited by this paper
• Biomarkers of tolerance in response to allergen immunotherapy.

  2013cited by this paper
• Allergen immunotherapy and tolerance.

  2013cited by this paper
• TSLP Elicits IL-33–Independent Innate Lymphoid Cell Responses to Promote Skin Inflammation

  2013cited by this paper
• Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study.

  2013cited by this paper
• Is intralymphatic immunotherapy ready for clinical use in patients with grass pollen allergy?

  2013cited by this paper
• A Nonallergenic Birch Pollen Allergy Vaccine Consisting of Hepatitis PreS–Fused Bet v 1 Peptides Focuses Blocking IgG toward IgE Epitopes and Shifts Immune Responses to a Tolerogenic and Th1 Phenotype

  2013cited by this paper
• Heterogeneity of antibody responses among clinical responders during grass pollen sublingual immunotherapy

  2013cited by this paper
• Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis.

  2013cited by this paper
• Allergen‐specific CD4+ T cell responses in peripheral blood do not predict the early onset of clinical efficacy during grass pollen sublingual immunotherapy

  2012cited by this paper
• Epigenetic modifications and improved regulatory T-cell function in subjects undergoing dual sublingual immunotherapy.

  2012cited by this paper
• Carrier‐bound Alt a 1 peptides without allergenic activity for vaccination against Alternaria alternata allergy

  2012cited by this paper
• Innate IL-13-producing nuocytes arise during allergic lung inflammation and contribute to airways hyperreactivity.

  2012cited by this paper
• Pulmonary innate lymphoid cells are major producers of IL‐5 and IL‐13 in murine models of allergic asthma

  2012cited by this paper
• Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses.

  2012cited by this paper
• A regulatory dendritic cell signature correlates with the clinical efficacy of allergen-specific sublingual immunotherapy.

  2012cited by this paper
• Optimisation of grass pollen nasal allergen challenge for assessment of clinical and immunological outcomes.

  2012cited by this paper
• Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy.

  2012cited by this paper
• Birch pollen immunotherapy results in long-term loss of Bet v 1-specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies.

  2012cited by this paper
• Unique and Cross-Reactive T Cell Epitope Peptides of the Major Bahia Grass Pollen Allergen, Pas n 1

  2012cited by this paper
• Carrier‐bound nonallergenic Der p 2 peptides induce IgG antibodies blocking allergen‐induced basophil activation in allergic patients

  2012cited by this paper
• Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study.

  2012cited by this paper
• Antibody repertoire complexity and effector cell biology determined by assays for IgE-mediated basophil and T-cell activation.

  2012cited by this paper
• SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial.

  2012cited by this paper
• Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

  2011cited by this paper
• Innate lymphoid cells promote lung tissue homeostasis following acute influenza virus infection

  2011cited by this paper
• Rhinitis , sinusitis , and upper airway disease Sustained 3-year efficacy of pre-and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen – induced rhinoconjunctivitis

  2011cited by this paper
• 100 years of hyposensitization: history of allergen‐specific immunotherapy (ASIT)

  2011cited by this paper
• Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta‐analysis

  2011cited by this paper
• Carrier-bound, nonallergenic Ole e 1 peptides for vaccination against olive pollen allergy.

  2011cited by this paper
• Dendritic cells modifi cation during sublingual immunotherapy in children with allergic symptoms to house dust mites

  2011cited by this paper
• Tolerogenic T cells, Th1/Th17 cytokines and TLR2/TLR4 expressing dendritic cells predominate the microenvironment within distinct oral mucosal sites

  2011cited by this paper
• Sustained effects of grass pollen AIT

  2011cited by this paper
• C1q regulation of dendritic cell development from monocytes with distinct cytokine production and T cell stimulation.

  2011cited by this paper
• Changes in basophil activation during grass‐pollen sublingual immunotherapy do not correlate with clinical efficacy

  2011cited by this paper
• Innate lymphoid cells promote lung-tissue homeostasis after infection with influenza virus

  2011cited by this paper
• Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses.

  2011cited by this paper
• Development and preliminary clinical evaluation of a peptide immunotherapy vaccine for cat allergy.

  2011cited by this paper
• Allergen-specific immunotherapy: towards combination vaccines for allergic and infectious diseases.

  2011cited by this paper
• Immunological Effects of Sublingual Immunotherapy: Clinical Efficacy Is Associated with Modulation of Programmed Cell Death Ligand 1, IL-10, and IgG4

  2010cited by this paper
• Sublingual grass pollen immunotherapy is associated with increases in sublingual Foxp3‐expressing cells and elevated allergen‐specific immunoglobulin G4, immunoglobulin A and serum inhibitory activity for immunoglobulin E‐facilitated allergen binding to B cells

  2010cited by this paper
• Developments in allergen‐specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen‐specific immunoglobulin E and T cell reactivity

  2010cited by this paper
• Molecular Determinants of T Cell Epitope Recognition to the Common Timothy Grass Allergen

  2010cited by this paper
• Programming dendritic cells to induce TH2 and tolerogenic responses

  2010cited by this paper
• Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties.

  2010cited by this paper
• Grass transcutaneous immunotherapy in children with seasonal rhinoconjunctivitis

  2010cited by this paper
• Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity

  2010cited by this paper
• Mechanisms and treatment of allergic disease in the big picture of regulatory T cells.

  2009cited by this paper
• House dust mite sublingual immunotherapy: the role for transforming growth factor-beta and functional regulatory T cells.

  2009cited by this paper
• Extensive IgE Cross-Reactivity towards the Pooideae Grasses Substantiated for a Large Number of Grass-Pollen-Sensitized Subjects

  2009cited by this paper
• Phleum pratense alone is sufficient for allergen‐specific immunotherapy against allergy to Pooideae grass pollens

  2009cited by this paper
• Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber.

  2009cited by this paper
• Peptide immunotherapy in allergic asthma generates IL-10–dependent immunological tolerance associated with linked epitope suppression

  2009cited by this paper
• Epigenetic mechanisms of regulation of Foxp3 expression.

  2009cited by this paper
• Distribution of Langerhans cells and mast cells within the human oral mucosa: new application sites of allergens in sublingual immunotherapy?

  2008cited by this paper
• Distinct regulation of IgE, IgG4 and IgA by T regulatory cells and toll‐like receptors

  2008cited by this paper
• Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.

  2008cited by this paper
• Oral dendritic cells mediate antigen-specific tolerance by stimulating TH1 and regulatory CD4+ T cells.

  2008cited by this paper
• Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa.

  2008cited by this paper
• Intralymphatic allergen administration renders specific immunotherapy faster and safer: A randomized controlled trial

  2008cited by this paper
• The immune privilege of the oral mucosa.

  2008cited by this paper
• Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation.

  2007cited by this paper
• Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells

  2007cited by this paper
• Grass Pollen Immunotherapy Induces an Allergen-Specific IgA2 Antibody Response Associated with Mucosal TGF-β Expression1

  2007cited by this paper
• Specific immunotherapy has long‐term preventive effect of seasonal and perennial asthma: 10‐year follow‐up on the PAT study

  2007cited by this paper
• Allergic rhinitis and its impact on asthma update: allergen immunotherapy.

  2007cited by this paper

• Current practices and future trends in cockroach allergen immunotherapy.

  2023cites this paper
• Molecular Aspects of Allergen-Specific Immunotherapy in Patients with Seasonal Allergic Rhinitis

  2023cites this paper
• Nasal cytology can predict clinical efficacy of subcutaneous immunotherapy in intermittent allergic rhinitis

  2022cites this paper
• Use of allergen immunotherapy for treatment of allergic conjunctivitis

  2020cites this paper
• Intranasal ovalbumin immunotherapy with mycobacterial adjuvant promotes regulatory T cell accumulation in lung tissues

  2018cites this paper
• When Allergen Immunotherapy Perfectly Meets its Need: A Case Report

  2017cites this paper
• New opportunities and challenges in the assessment of drugs for atopic diseases

  2016cites this paper